The Association’s visiting delegation participated in two high-level panel discussions
The Pharmaceutical Research and Manufacturers Association of the Gulf (PHRMAG has reaffirmed its role as a catalyst for regional healthcare transformation at the recently concluded World Health Expo (WHX in Dubai).
During the event, PHRMAG’s delegation participated in two high-level panel discussions highlighting the Gulf’s growing prominence as a hub for life sciences innovation and biotech investment.
PHRMAG’s Chairman Sameh El Fangary participated in a strategic leadership dialogue entitled ‘The New Era of Health Systems Leadership: Rewriting the Blueprint’, which convened senior government leaders, and global CEOs to examine the policy shifts and governance models shaping the next generation of intelligence-driven health systems.
System enabler
During the session, Sameh highlighted the role of the bio-innovative pharmaceutical and life sciences industry as a system enabler, contributing beyond medicines to support workforce development, data stewardship, interoperability, and evidence generation.
Following the inauguration of the World Health Expo Biotech & Life Sciences Zone, PHRMAG’s Vice Chairman Ashraf Mallak joined a strategic panel ‘Building a Globally Competitive Biotech Ecosystem’, alongside senior regional and global leaders from government, industry, and academia.
Commenting on the discussion, Ashraf said: “Globally competitive biotech ecosystems are built on trust, transparency, and collaboration. When markets provide regulatory confidence and structured dialogue, companies are empowered to invest, partner, manufacture, and scale with confidence,” commented Ashraf.
Biotech strategy
Shahad Mahdi, Secretary General, PHRMAG, also moderated a panel discussion titled ‘Unveiling the Next Wave of Regional Biotech & Life Sciences Strategy and Direction’, which brought together senior leaders from across the GCC region to discuss how nations are defining their biotech strategy for the future in terms of policies, regulations, and strategic priorities.
Through these engagements, PHRMAG highlighted its strategic commitment to fostering equitable access to advanced therapies, strengthening regulatory maturity, and advancing frameworks that support real-world evidence, precision health, and value-based care models.
